Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML

Next Previous
Trial Profile

Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tigecycline (Primary)
  • Indications Acute myeloid leukaemia; Bacterial infections
  • Focus Adverse reactions; Biomarker

Most Recent Events

  • 14 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
  • 29 Jul 2013 The study is on-track for completion in Q3 2013, according to a company media release.
  • 17 Apr 2013 This study is nearing completion and data are expected this summer, according to a Stem Cell Therapeutics Corp. media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top